×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IONS – ionis pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IONS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/27
07:00 am
ions
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
Low
Report
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
2/27
03:58 am
ions
Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/27
12:00 am
ions
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90 [Yahoo! Finance]
Low
Report
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90 [Yahoo! Finance]
2/26
09:55 am
ions
Ionis Pharmaceuticals (IONS) had its price target raised by Stifel Nicolaus from $73.00 to $77.00. They now have a "hold" rating on the stock.
Low
Report
Ionis Pharmaceuticals (IONS) had its price target raised by Stifel Nicolaus from $73.00 to $77.00. They now have a "hold" rating on the stock.
2/26
07:00 am
ions
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
Low
Report
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
2/25
07:05 pm
ions
Ionis Pharmaceuticals (IONS) was given a new $95.00 price target by Morgan Stanley. They now have an "overweight" rating on the stock.
Low
Report
Ionis Pharmaceuticals (IONS) was given a new $95.00 price target by Morgan Stanley. They now have an "overweight" rating on the stock.
2/25
04:27 pm
ions
Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
2/25
03:58 pm
ions
Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by Needham & Company LLC.
Low
Report
Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by Needham & Company LLC.
Date
Time
Symbol
Company Name
Action
%Chg
2/25/2026
07:00 am
ions
ionis pharmaceuticals, inc.
MISS
Report
-1.2%
ionis pharmaceuticals, inc.
10/29/2025
07:00 am
ions
ionis pharmaceuticals, inc.
BEAT
Report
-2.9%
ionis pharmaceuticals, inc.
7/30/2025
07:00 am
ions
ionis pharmaceuticals, inc.
BEAT
Report
4.5%
ionis pharmaceuticals, inc.
4/30/2025
07:00 am
ions
ionis pharmaceuticals, inc.
BEAT
Report
1.4%
ionis pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/26
04:29 pm
ions
Form 10-K IONIS PHARMACEUTICALS For: Dec 31
Low
Report
Form 10-K IONIS PHARMACEUTICALS For: Dec 31
2/25
07:01 am
ions
Form 8-K IONIS PHARMACEUTICALS For: Feb 25
Medium
Report
Form 8-K IONIS PHARMACEUTICALS For: Feb 25
2/17
10:29 am
ions
Form SCHEDULE 13G/A IONIS PHARMACEUTICALS Filed by: T. Rowe Price Investment Management, Inc.
Low
Report
Form SCHEDULE 13G/A IONIS PHARMACEUTICALS Filed by: T. Rowe Price Investment Management, Inc.
2/13
07:41 pm
ions
Form 4/A IONIS PHARMACEUTICALS For: Feb 02 Filed by: BENNETT C FRANK
Low
Report
Form 4/A IONIS PHARMACEUTICALS For: Feb 02 Filed by: BENNETT C FRANK
2/13
07:40 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Feb 11 Filed by: PARSHALL B LYNNE
Low
Report
Form 4 IONIS PHARMACEUTICALS For: Feb 11 Filed by: PARSHALL B LYNNE
2/13
07:40 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Feb 13 Filed by: Swayze Eric
Low
Report
Form 4 IONIS PHARMACEUTICALS For: Feb 13 Filed by: Swayze Eric
2/13
04:05 pm
ions
Form 144 IONIS PHARMACEUTICALS Filed by: Swayze Eric
Low
Report
Form 144 IONIS PHARMACEUTICALS Filed by: Swayze Eric
2/11
04:03 pm
ions
Form 144 IONIS PHARMACEUTICALS Filed by: PARSHALL B LYNNE
Medium
Report
Form 144 IONIS PHARMACEUTICALS Filed by: PARSHALL B LYNNE
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Form 4 IONIS PHARMACEUTICALS For: Mar 19 Filed by: CROOKE STANLEY T
7.8%
3/3 Form 4 IONIS PHARMACEUTICALS For: Feb 29 Filed by: O'NEIL PATRICK R. 7.6%
3/26 Ionis Pharmaceuticals Inc (NASDAQ: IONS) had its price target lowered by analysts at Cantor Fitzgerald from $65.00 to $56.00. They now have a "neutral" rating on the stock. 6.4%
4/8 Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs 4.9%
7/17 Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: McDevitt Damien 4.5%
9/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating. 4.4%
4/23 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
2/16 Ionis Pharmaceuticals Looks Undervalued - Q4, FY Earnings Will Be Important [Seeking Alpha] 3.6%
9/10 Ionis Pharmaceuticals, Inc. (IONS) Presents at 17th Annual Morgan Stanley Global Healthcare Conference (Transcript) [Seeking Alpha] 3.2%
8/7 Q2/2019 6/30/2019 EPS -0.010 ZacksConsensus -0.270 ActVsEst 0.260 - Beat 3.2%
3/3 Form 4 IONIS PHARMACEUTICALS For: Feb 29 Filed by: O'NEIL PATRICK R. 7.6%
3/26 Ionis Pharmaceuticals Inc (NASDAQ: IONS) had its price target lowered by analysts at Cantor Fitzgerald from $65.00 to $56.00. They now have a "neutral" rating on the stock. 6.4%
4/8 Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs 4.9%
7/17 Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: McDevitt Damien 4.5%
9/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating. 4.4%
4/23 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
2/16 Ionis Pharmaceuticals Looks Undervalued - Q4, FY Earnings Will Be Important [Seeking Alpha] 3.6%
9/10 Ionis Pharmaceuticals, Inc. (IONS) Presents at 17th Annual Morgan Stanley Global Healthcare Conference (Transcript) [Seeking Alpha] 3.2%
8/7 Q2/2019 6/30/2019 EPS -0.010 ZacksConsensus -0.270 ActVsEst 0.260 - Beat 3.2%
TOP News Decliners
3/15
Researchers Behind Spinraza Win Breakthrough Prize [Forbes]
-9.9%
7/22 Biogen Earnings: Here's What Investors Are Hoping To See In Report [Investor's Business Daily] -8.8%
3/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.0%
10/16 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.6%
3/20 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $49.00 price target on the stock. -5.4%
2/26 Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.9%
6/6 Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders -4.7%
9/30 Form 8-K IONIS PHARMACEUTICALS For: Sep 27 -4.6%
2/28 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at TheStreet from a "c" rating to a "b-" rating. -4.2%
12/16 Positive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trial -3.8%
7/22 Biogen Earnings: Here's What Investors Are Hoping To See In Report [Investor's Business Daily] -8.8%
3/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.0%
10/16 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.6%
3/20 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $49.00 price target on the stock. -5.4%
2/26 Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.9%
6/6 Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders -4.7%
9/30 Form 8-K IONIS PHARMACEUTICALS For: Sep 27 -4.6%
2/28 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at TheStreet from a "c" rating to a "b-" rating. -4.2%
12/16 Positive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trial -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: